Filing Flows

Filing Flows › Companies › Profound Medical › Cash flow

Profound Medical cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$5.0M in Q3 2026 · −$31.5M over twelve months

Operating cash flow−$5.0M
Free cash flow−$5.0M

Analysis

In Q3 2026, Profound Medical generated −$5.0M of operating cash flow. That is $4.6M more than in Q3 2025 (−$9.6M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$31.5M; the largest uses were operating cash flow ($31.5M); besides operations, cash came from other financing ($41.5M); the cash balance rose by $8.5M.

Operating cash flow was −$5.0M against net income of −$7.7M. The largest differences: payables +$2.5M, receivables −$1.4M, deferred revenue +$602K.

Free cash flow

Profound Medical: free cash flow by quarterProfound Medical: free cash flow by quarter−$5.9MQ4 2024−$8.3MQ1 2025−$13.7MQ2 2025−$9.6MQ3 2025−$6.6MQ4 2025−$8.6MQ1 2026−$11.3MQ2 2026−$5.0MQ3 2026
Operating cash flow less capital spending.
Profound Medical: operating cash flow against capital spendingProfound Medical: operating cash flow against capital spendingOperating cash flowCapital spending−$5.9M$0Q4 2024−$8.3M$0Q1 2025−$13.7M$0Q2 2025−$9.6M$0Q3 2025−$6.6M$0Q4 2025−$8.6M$0Q1 2026−$11.3M$0Q2 2026−$5.0M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$5.0M, Capital spending $0.

Capital allocation, year by year

Profound Medical: where the cash came from (up) and went (down), by fiscal yearProfound Medical: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$22.4MFY2021: Capital spending −$32KFY2021FY2022: Operating cash flow −$25.8MFY2022FY2023: Operating cash flow −$22.6MFY2023: Net borrowing −$912KFY2023: Shares issued $245K$245KFY2023FY2024: Operating cash flow −$23.5MFY2024: Net borrowing −$2.0MFY2024: Shares issued $62.2M$62.2MFY2024FY2025: Operating cash flow −$38.2MFY2025: Net borrowing −$290KFY2025: Shares issued $42.4MFY2025: Capital spending −$176K$42.4MFY2025
Over these 5 years operating cash flow totalled −$132M; the largest uses were operating cash flow ($132M) and net borrowing ($3.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$33.3M
Debt$4.5M
Net cash$28.8M
Due within a year$4.5M
Cash runway13 months

Profound Medical is burning cash: its operations consume cash, a free cash flow of −$31.5M a year at the current rate against $33.3M of cash and investments: a runway of about 13 months; $4.5M of debt also comes due within a year, which would need refinancing or new money before any new financing.

Where the cash came from and went

Profound Medical: sources (+) and uses (−) of cash, Q3 2026Profound Medical: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$5.0MCash drawn (+) / kept (−)$4.9MExchange rates$42KNot reconciled$36K
Profound Medical: sources (+) and uses (−) of cash, TTM to Q3 2026Profound Medical: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$41.5MOperating cash flow−$31.5MCash drawn (+) / kept (−)−$8.5MExchange rates−$1.2MNot reconciled−$242K

From profit to cash

Profound Medical: net income to operating cash flow, Q3 2026Profound Medical: net income to operating cash flow, Q3 2026Net income−$7.7MDepreciation & amortization$133KStock-based pay$257KDeferred taxes−$12KReceivables−$1.4MInventory$242KPayables$2.5MDeferred revenue$602KIncome taxes payable$13KOperating cash flow−$5.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$5.0M——$4.9M−$5.0M
Q2 2026−$11.3M——$12.0M−$11.3M
Q1 2026−$8.6M——$9.4M−$8.6M
Q4 2025−$6.6M——−$34.9M−$6.6M
Q3 2025−$9.6M——$10.4M−$9.6M
Q2 2025−$13.7M——$11.2M−$13.7M
Q1 2025−$8.3M−$290K—$8.5M−$8.3M
Q4 2024−$5.9M−$159K$39.2M−$27.8M−$5.9M

Profound Medical: income statement and cash flow

Profound Medical, Q3 2026: revenue $9.8M (+86% year over year), operating margin -79.6%. The chart follows the revenue to costs, profit and cash.

Profound Medical: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.